FDA approves Emergent BioSolutions’ anthrax treatment

(Reuters) – Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the U.S. Department of Health and Human Services (HHS). Emergent Bio developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS. The drug is already being stored in the U.S. Strategic National Stockpile, the

Source: news.yahoo.com

See on Scoop.itBiodefense News

Leave a Reply